Method for treating abdominal discomfort

a chloride channel and abdominal discomfort technology, applied in the field of prostaglandin, can solve the problems of abdominal discomfort, abdominal discomfort may also occur, not known as to drugs, etc., and achieve the effect of significant effect on abdominal discomfor

Inactive Publication Date: 2010-11-25
SUCAMPO
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]The present inventor has conducted intensive studies and found that a chloride channel opener, especially prostaglandin compound have a significant effect on abdominal discomfort, especially, on functional gastrointestinal disorders such as IBS and FD, which resulted in the completion of the present invention.

Problems solved by technology

Various disorders may cause abdominal discomfort.
It is also known that abdominal discomfort may also occur as a side effect of drug, medication or surgical procedure.
However, it is not yet known as to the drug that may be used for safely and effectively treating abdominal discomfort.
Patients having functional gastrointestinal disorders often report abdominal discomfort.
No systematic method has been established for treating such disorder.
However, it is not known how chloride channel openers and / or prostaglandin compounds act on abdominal discomfort, or the functional gastrointestinal disorders.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating abdominal discomfort
  • Method for treating abdominal discomfort
  • Method for treating abdominal discomfort

Examples

Experimental program
Comparison scheme
Effect test

example 1

Methods

[0125]Patients with irritable bowel syndrome (IBS) were randomly allocated to the following two treatment groups.[0126]Group 1: Test substance (13,14-dihydro-15-keto-16,16-difluoro-PGE1) 48 μg total (24 μg / breakfast+24 μg / dinner)[0127]Group 2: Matching placebo (placebo / breakfast+placebo / dinner)

[0128]Each group underwent two weeks washout period and then began to administer oral test substance (capsules) or placebo (capsules) daily for 4 weeks. Test substance or placebo was taken two times a day (b.i.d) at breakfast with food and at least 8 ounces of water and at dinner with food and at least 8 ounces of water. Patients were asked to evaluate abdominal discomfort upon waking in the morning, using a 5-point scale (Score: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe) at 4 weeks after the initiation of the treatments.

[0129](Results)

[0130]As shown in Table 1, test substance of this invention significantly improved the abdominal discomfort in the patients with IBS.

TABLE 1E...

example 2

Methods

[0131]Patients with occasional constipation were randomly allocated to the following two treatment groups.[0132]Group 1: Test substance (13,14-dihydro-15-keto-16,16-difluoro-PGE1) 48 μg total (24 μg / breakfast+24 μg / dinner)[0133]Group 2: Matching placebo (placebo / breakfast+placebo / dinner)

[0134]Each group underwent two weeks washout period and then began to administer oral test substance (capsules) or placebo (capsules) daily for 4 weeks. During the washout period, the patient's bowel habit was documented to confirm the existence of constipation. Constipation is defined as, on average, less than three spontaneous bowel movements per week. All existing laxative medication was withdrawn at the start of the washout period and the patients were instructed not to change their diet or lifestyle during the study.

[0135]Test substance or placebo was taken orally for a total treatment period of 4 weeks; it was taken two times a day (b.i.d) at breakfast with food and at least 8 ounces of ...

example 3

Methods

[0139]Patients with irritable bowel syndrome (IBS) were randomly allocated to the following two treatment groups.[0140]Group 1: Test substance (13,14-dihydro-15-keto-16,16-difluoro-PGE1) 48 μg total (24 μg / breakfast+24 μg / dinner)[0141]Group 2: Matching placebo (placebo / breakfast+placebo / dinner)

[0142]Each group underwent two weeks washout period and then began to administer oral test substance (capsules) or placebo (capsules) daily for 4 weeks. Test substance or placebo was taken two times a day (b.i.d) at breakfast with food and at least 8 ounces of water and at dinner with food and at least 8 ounces of water. The patients were asked to evaluate abdominal bloating upon waking in the morning, using a 5-point scale (Score: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe) at 4 weeks after the initiation of the treatments.

[0143](Results)

[0144]As shown in Table 3, test substance of this invention significantly improved the abdominal bloating in patients with IBS.

TABLE 3Effec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
Stressaaaaaaaaaa
structureaaaaaaaaaa
Login to view more

Abstract

Disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of abdominal discomfort. Further disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of functional gastrointestinal disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This is a continuation of U.S. application Ser. No. 10 / 745,689 filed Dec. 29, 2003, which claims the benefit of provisional application Nos. 60 / 436,462 and 60 / 436,463 both filed Dec. 27, 2002, the contents of all of which are incorporated herein by reference in their entireties.TECHNICAL FIELD[0002]The present invention relates to a method for treating abdominal discomfort with a chloride channel opener, especially, a prostaglandin compound.[0003]Further, the present invention relates to a method for treating functional gastrointestinal disorders with a chloride channel opener, especially, a prostaglandin compound.BACKGROUND ART[0004]Abdominal indefinite complaint or abdominal discomfort is most often experienced in our daily lives, and it includes heartburn, nausea, emesis, anorexia, epigastric pain, abdominal bloating, chronic abdominal pain, abdominal discomfort, abnormal bowel movement such as constipation and diarrhea and the like. V...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/352A61K31/19A61P1/00A61K31/557A61K31/5575A61P1/10
CPCA61K31/557C07C57/56A61K31/5575A61K31/5585A61P1/00A61P1/04A61P1/10A61P1/14A61P43/00
Inventor UENO, RYUJIKUNO, SACHIKO
Owner SUCAMPO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap